1. ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer
   Iris C. Salaroglio et al, 2019, IJMS CrossRef
2. Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance
   Susana Machado et al, 2020, Cancers CrossRef
3. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib
   Nianxue Wang et al, 2021, Cancer Chemother Pharmacol CrossRef
4. The Critical Role of TRIB2 in Cancer and Therapy Resistance.
   Victor Mayoral-Varo et al, 2021, Cancers (Basel) CrossRef
5. TRIB2 Stimulates Cancer Stem-Like Properties through Activating the AKT-GSK3β-β-Catenin Signaling Axis
   Dae Kyoung Kim et al, 2021, Mol.Cells CrossRef
6. RFWD2 Knockdown as a Blocker to Reverse the Oncogenic Role of TRIB2 in Lung Adenocarcinoma
   Ruimin Hao et al, 2021, Front. Oncol. CrossRef
7. Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis
   Silvia Di Giacomo et al, 2022, Pharmaceutics CrossRef